A cura di: Carlo Crispino, Antonino Cammarata 
Autori: Nosaki K, Saka H, Hosomi Y, Baas P, de Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, Noguchi K, Han SR, Piperdi B, Kush DA, Lopes G.
Rif. Biblio: Lung Cancer 2019;135:188-95.
“Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.”

A cura di: Stefania Greco
Autori: Suissa S, Dell'Aniello S, Gonzalez AV, Ernst P
Rif. biblio: Eur Respir J 2019. pii: 1901720.
“Inhaled corticosteroid use and the incidence of lung cancer in COPD”

A cura di: Carlo Crispino, Antonino Cammarata
Autori: Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, Hermes B, Çay Şenler F, Csőszi T, Fülöp A, Rodríguez-Cid J, Wilson J, Sugawara S, Kato T, Lee KH, Cheng Y, Novello S, Halmos B, Li X, Lubiniecki GM, Piperdi B, Kowalski DM; KEYNOTE-407 Investigators.
Rif. biblio: N Engl J Med 2018;379:2040-51
“Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer”

A cura di: Valeria Stati, Filippo de Marinis
Autori: Reck M, Mok TSK, Nishio M, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Lee A, Coleman S, Deng Y, Kowanetz M, Shankar G, Lin W, Socinski MA; IMpower150 Study Group.
Rif. biblio: Lancet Respir Med 2019;7:387-401.
"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial."

A cura di: Valeria Stati, Filippo de Marinis
Autori: Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM
Rif. biblio: J Clin Oncol 2019:JCO1900189. [Epub ahead of print]
“Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications”